Source study not identified
Story checked
ScionxBio announces collaboration to develop long-acting xRNA therapeutics (opens in a new tab)
news-medical.net · 2026-10-21
Short answer
Source study not identifiedStudy not confirmed.
The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
ScionxBio announces collaboration to develop long-acting xRNA therapeutics
news-medical.net · 2026-10-21
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
No source study could be identified.
The available search results did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.
View article claimsSearch result
No source study found.
The available search results did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.
Evidence layer
Claim by claim
The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 5Not checkedScionxBio announced a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialize extended-exposure versions of certain Sanofi mRNA candidates using ScionxBio's TERA platform.View evidenceHide evidence
As statedworldwide
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 2 of 5Not checkedThe company says the collaboration is meant to expand the xRNA modality toward novel long-acting applications across multiple potential indications.View evidenceHide evidence
As statedacross a multitude of potential indications
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 3 of 5Not checkedScionxBio says its platform uses deep learning and chemical design to create molecules with greater stability and resistance to enzymatic degradation than traditional mRNA, enabling sustained high-level protein expression in vivo.View evidenceHide evidence
As statedgreater stability and resistance to enzymatic degradation
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 4 of 5Not checkedThe article says the disease areas covered by the collaboration are undisclosed, but are intended for conditions where sustained protein expression is essential and may include inherited and acquired protein deficiencies, cardiometabolic, or immune corrective modulators.View evidenceHide evidence
As statedundisclosed
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Claim 5 of 5Not checkedScionxBio will lead optimization through in vivo validation, after which Sanofi will handle remaining preclinical work, IND-enabling studies, clinical development, manufacturing, and worldwide commercialization.View evidenceHide evidence
As statedworldwide commercialization
Not checked
No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.
Method layer
Study not confirmed.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
Crossref · 15 candidate papers
Figure 5: Relative mRNA expression levels of AQP 1-6 under different duration of low temperature treatment.
Crossref
Figure 10: The mRNA and protein expression levels of TFRC.
Crossref
Supplemental Information 3: Relative mRNA expression levels of AQP 1-6 under different duration of low temperature treatment.
Crossref
Figure 2: The effect of GDF11 on mRNA and protein expression.
Crossref
Figure 3: The expression of DNAJC1 mRNA and protein after siRNA transfection.
Crossref